RxDoctor Payments DataLook up a doctor →

Cinthia Bateman, MD

Interventional Cardiology · Littleton, CONPI 1548258726

Payments from drug & device makers

$222,660in general payments, 2019–2025

Across 790 payments — averaging $281.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$131K
  • Shockwave Medical, Inc$78K
  • Abiomed$4K
  • Siemens Medical Solutions USA, Inc.$1K
  • Amgen$1K
  • Novartis$547
  • plus $6K from 44 others

What the payments were for

  • Consulting fees$20,00020%
  • Speaking & faculty fees$46,30046%
  • Travel & lodging$6,3276%
  • Food & beverage$28,19628%
  • Education$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$222,660 in reported general payments places this provider in the 85th percentile of 111 interventional cardiology providers in Colorado.

See all interventional cardiology providers in Colorado

Medicare billing

Part B allowed, 2024
$176,676
Medicare patients
655
Services billed
1,511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban337$495,555
Repatha SureclickEvolocumab264$293,453
XareltoRivaroxaban193$278,623
EntrestoSacubitril/Valsartan57$103,322
FarxigaDapagliflozin Propanediol63$75,318
JardianceEmpagliflozin49$71,695
Praluent PenAlirocumab79$56,883
MultaqDronedarone Hcl14$31,632
Repatha PushtronexEvolocumab25$25,951
Repatha SyringeEvolocumab12$12,097
BrilintaTicagrelor12$11,074
Rosuvastatin Calcium550$8,665
Nebivolol Hcl81$7,782
Atorvastatin Calcium779$6,861
ClopidogrelClopidogrel Bisulfate432$5,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$531$495,555337 claims
Johnson & JohnsonXarelto$344$278,623193 claims
NovartisEntresto$547$103,32257 claims
AstraZenecaFarxiga, Brilinta$493$86,39275 claims
Boehringer IngelheimJardiance$489$71,69549 claims
Sanofi-aventis U.S. LLCMultaq$398$31,63214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 111 interventional cardiology providers in Colorado.

Other interventional cardiology in Littleton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →